Attralus
Attralus is pioneering a transformative approach to systemic amyloidosis with its pan-amyloid removal (PAR) platform, which targets the underlying disease pathology by clearing toxic amyloid deposits from vital organs. The company's strategy is built on deep amyloid research expertise and includes both therapeutic biologics and a proprietary diagnostic imaging agent. With a lead program in Phase 1/2 trials and backing from prominent life science investors like venBio and Sarissa Capital, Attralus is positioned to potentially shift the treatment paradigm from slowing progression to enabling disease reversal.
Private Company
Total funding raised: $282M
AI Company Overview
Attralus is pioneering a transformative approach to systemic amyloidosis with its pan-amyloid removal (PAR) platform, which targets the underlying disease pathology by clearing toxic amyloid deposits from vital organs. The company's strategy is built on deep amyloid research expertise and includes both therapeutic biologics and a proprietary diagnostic imaging agent. With a lead program in Phase 1/2 trials and backing from prominent life science investors like venBio and Sarissa Capital, Attralus is positioned to potentially shift the treatment paradigm from slowing progression to enabling disease reversal.
Technology Platform
Proprietary Pan-Amyloid Removal (PAR) platform for developing biologics that bind to a common structural motif in amyloid fibrils, enabling clearance of toxic deposits across all types of systemic amyloidosis.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Attralus competes with large pharma (Pfizer, Alnylam, AstraZeneca) that offer approved therapies slowing amyloid production, but it is differentiated by its focus on clearing existing amyloid deposits. Its main competitive advantage is the potential for a single pan-amyloid therapeutic, whereas competitors' drugs are specific to ATTR or AL amyloidosis.